Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism MMP1 inhibitors(Matrix metalloproteinase-1 inhibitors), uPA inhibitors(Urokinase plasminogen activator inhibitors), Angiogenesis inhibitors + [1] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC18H25N3O5 |
InChIKeyOIVAPLYJZKBFMV-KGLIPLIRSA-N |
CAS Registry166245-54-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neovascularization, Pathologic | Preclinical | Japan | 17 Dec 1997 | |
Neoplasms | Preclinical | Japan | - | - |
Neoplasms | Preclinical | Japan | - | - |